Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) CEO Emily M. Leproust sold 492 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $38.73, for a total transaction of $19,055.16. Following the completion of the transaction, the chief executive officer now directly owns 660,474 shares of the company's stock, valued at approximately $25,580,158.02. The trade was a 0.07 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Twist Bioscience Trading Down 3.5 %
NASDAQ:TWST opened at $36.19 on Friday. Twist Bioscience Co. has a 52 week low of $27.41 and a 52 week high of $60.90. The firm's fifty day moving average is $43.80 and its 200-day moving average is $45.10. The firm has a market cap of $2.16 billion, a P/E ratio of -10.71 and a beta of 2.34. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping analysts' consensus estimates of ($0.62) by $0.09. The firm had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business's revenue was up 24.1% compared to the same quarter last year. During the same period last year, the business posted ($0.75) EPS. Equities analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current year.
Institutional Investors Weigh In On Twist Bioscience
Hedge funds have recently added to or reduced their stakes in the business. Versant Capital Management Inc boosted its holdings in shares of Twist Bioscience by 547.2% during the 1st quarter. Versant Capital Management Inc now owns 686 shares of the company's stock worth $27,000 after buying an additional 580 shares in the last quarter. Van ECK Associates Corp lifted its position in shares of Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after acquiring an additional 267 shares during the period. Wilmington Savings Fund Society FSB bought a new position in Twist Bioscience during the third quarter worth $34,000. Banque Transatlantique SA acquired a new stake in Twist Bioscience in the fourth quarter worth $43,000. Finally, GF Fund Management CO. LTD. bought a new stake in Twist Bioscience in the fourth quarter valued at $58,000.
Wall Street Analysts Forecast Growth
TWST has been the subject of a number of research reports. Barclays set a $58.00 price objective on Twist Bioscience and gave the company an "overweight" rating in a report on Monday, February 3rd. Robert W. Baird boosted their price target on Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a report on Tuesday, February 4th. Guggenheim set a $50.00 price objective on Twist Bioscience in a research note on Friday, March 28th. JPMorgan Chase & Co. lifted their target price on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a research report on Tuesday, February 4th. Finally, Scotiabank restated an "outperform" rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $54.10.
View Our Latest Stock Report on TWST
About Twist Bioscience
(
Get Free Report)
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
